Evidence map›Paper›PMID 40833332›Full record

ArticleImmunotherapy2025

Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy.

Giulia Mazzaschi, Roberto Rosati, Simona D'Agnelli, Roberta Minari, Francesca Trentini, Prisca Tamarozzi, Martina Manini, Martina Zinelli Ronzoni, Alessandra Dodi, Letizia Gnetti and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Giulia MazzaschiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Roberto RosatiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Simona D'AgnelliMedical Oncology Unit, University Hospital of Parma, Parma, Italy.
Roberta MinariMedical Oncology Unit, University Hospital of Parma, Parma, Italy.
Francesca TrentiniDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Prisca TamarozziDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Martina ManiniDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Martina Zinelli RonzoniDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Alessandra DodiMedical Oncology Unit, University Hospital of Parma, Parma, Italy.
Letizia GnettiPathology Unit, University Hospital of Parma, Parma, Italy.
Lorena BottarelliDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Cinzia AzzoniDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Gianmarco MartinesMedical Oncology Unit, University Hospital of Parma, Parma, Italy.
Monica PluchinoMedical Oncology Unit, University Hospital of Parma, Parma, Italy.
Ilaria ToscaniDepartment of Oncology-Hematology, Ospedale "G. da Saliceto", Piacenza, Italy.
Alessandro LeonettiMedical Oncology Unit, University Hospital of Parma, Parma, Italy.
Fabiana PerroneMedical Oncology Unit, University Hospital of Parma, Parma, Italy.
Paola BordiMedical Oncology Unit, University Hospital of Parma, Parma, Italy.
Giovanni BocchialiniThoracic Surgery Unit, University Hospital of Parma, Parma, Italy.
Luca AmpolliniDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Federico QuainiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Marcello TiseoDepartment of Medicine and Surgery, University of Parma, Parma, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimA translational multiscale approach, encompassing tumor immune microenvironment (TIME), circulating immune-inflammatory benchmarks, and transcriptomic profiles, was undertaken to identify prognostic biomarkers of immunotherapy (IT) efficacy in patients with advanced pleural mesothelioma (PM).

methodsAdvanced PM patients (

resultsHigher baseline CD4

conclusionParallel immune and transcriptomic profiling identifies biomarkers predictive of IT benefit in PM.

Indexed as

ImmunotherapyMesotheliomaPleural NeoplasmsAgedBiomarkers, TumorFemaleHumansIpilimumabMaleMesothelioma, MalignantMiddle AgedNivolumabPrognosisTranscriptomeTumor MicroenvironmentBiomarkers, TumorIpilimumabNivolumabbiomarkersCD4+ T cellsgranzyme BImmunotherapyperipheral blood immunophenotypingPleural mesotheliomatranscriptomicstumor immune microenvironment

Identifiers

PMID40833332
PMCPMC12439584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.